Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients

Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients

Highlights • First report of proteomic analysis applied to severe asthma biopsies obtained before and after 12 month omalizumab treatment. • Identification of galectin-3 as predictive biomarker of bronchial basal membrane modulation upon omalizumab treatment. • Galectin-3 is a stable marker up 12 mo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunology letters 2014-11, Vol.162 (1), p.2-10
Hauptverfasser: Mauri, Pierluigi, Riccio, Anna Maria, Rossi, Rossana, Di Silvestre, Dario, Benazzi, Louise, De Ferrari, Laura, Negro, Roberto Walter Dal, Holgate, Stephen T, Canonica, Giorgio Walter
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Airway Remodeling
Allergy and Immunology
Anti-Asthmatic Agents - therapeutic use
Antibodies, Anti-Idiotypic - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Asthma - drug therapy
Asthma - metabolism
Asthma - pathology
Biomarkers - metabolism
Biopsy
Bronchi - metabolism
Bronchi - pathology
Cluster Analysis
Female
Galectin 3 - metabolism
Galectin-3
Humans
Immunohistochemistry
Interactome
Male
Middle Aged
Odds Ratio
Omalizumab
Prognosis
Protein Interaction Maps
Proteome
Proteomics
Proteomics analysis
Severe asthma
Severity of Illness Index
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • First report of proteomic analysis applied to severe asthma biopsies obtained before and after 12 month omalizumab treatment. • Identification of galectin-3 as predictive biomarker of bronchial basal membrane modulation upon omalizumab treatment. • Galectin-3 is a stable marker up 12 months after treatment, confirmed by staining the biopsies. • The interactome analysis showed also reduction of myosins and actins after omalizumab treatment. • First report in humans of reduction of the musculaire component of bronchi due to a therapeutic intervention.
ISSN:0165-2478
1879-0542
DOI:10.1016/j.imlet.2014.08.010